The Drug Burosumab Demonstrates Long-Term Benefits for X-Linked Hypophosphatemia
According to a story from Medscape, the drug burosumab (marketed as Crysvita) demonstrated its ability to provide long term benefits for nearly two years to patients with the rare disease…